# OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Study · id `cardio:ct-nct01955200` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01955200](<https://clinicaltrials.gov/study/NCT01955200>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01955200

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1724 participants.

## Technical summary

Registry record NCT01955200. Randomized; no masking; primary purpose treatment. Start 2013-10-05 (actual); primary completion 2016-12-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1724 participants (enrolled count; ClinicalTrials.gov record NCT01955200, source copy `cardio:ctgov-nct01955200-2020-08-18`, retrieved 2026-10-26)
- Started: 2013-10-05 (actual) (ClinicalTrials.gov record NCT01955200, source copy `cardio:ctgov-nct01955200-2020-08-18`, retrieved 2026-10-26)
- Primary completion: 2016-12-26 (actual) (ClinicalTrials.gov record NCT01955200, source copy `cardio:ctgov-nct01955200-2020-08-18`, retrieved 2026-10-26)
- Completion: 2017-11-28 (actual) (ClinicalTrials.gov record NCT01955200, source copy `cardio:ctgov-nct01955200-2020-08-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01955200, source copy `cardio:ctgov-nct01955200-2020-08-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01955200-2020-08-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
- Acronym: OPTIMA-2
- Condition: Coronary Artery Disease
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Cilostazol
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Clopidogrel
- Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
- Lead sponsor class: OTHER
- Collaborator: National Natural Science Foundation of China
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)
- Registry lists this organization as a collaborator: National Natural Science Foundation of China (`cardio:org-national-natural-science-foundation-of-china`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on-treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)-2 Trial (`cardio:pubmed-34611892`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 32d93162830acff400b03c098bafc348c67eaeae702ca0d8c08d522c91dcf98c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
